NEW YORK, Sept. 6 – MediChem and Rigel Pharmaceuticals announced a two-year structural proteomics collaboration to search for new treatments in the area of ubiquitin ligases, which are involved in cell division and the progression of some cancers.

Under the terms of the deal, MediChem's Emerald BioStructures structural proteomics unit will express, purify, and crystallize proteins that Rigel is focusing on in its oncology program. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.